About
Single Particle Tracking
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
1,386
By Phase
PHASE2/PHASE3: 1PHASE1/PHASE2: 2PHASE2: 3PHASE1: 3
By Status
RECRUITING: 5COMPLETED: 4
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06697301Lead Sponsor
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
PHASE2/PHASE3Recruiting
740 participants
Started: May 22, 2025 · Completed: Dec 31, 2040
NCT06907043Lead Sponsor
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
PHASE1/PHASE2Recruiting
130 participants
Started: Apr 30, 2025 · Completed: Dec 31, 2028
NCT06246110Lead Sponsor
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
PHASE2Recruiting
70 participants
Started: Feb 6, 2024 · Completed: Dec 31, 2027
NCT06253130Lead Sponsor
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
70 participants
Started: Dec 11, 2023 · Completed: Dec 1, 2026
NCT04819373Lead Sponsor
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
PHASE2Completed
1 participants
Started: Aug 30, 2021 · Completed: May 1, 2023
Locations (1)
Headquarters
Millbrae, CA, United States
Map
Loading map...